EZH2 and plasma cell myeloma: We have previously analysed DNA from almost 500 cases of newly diagnosed myeloma patients and their paired germline controls.30, 31 No patients had mutations in EZH2, but 3% of patients had potentially inactivating mutations or deletions in its partner demethylase KDM6A, with evidence of a negative effect on patient outcomes.